Aducanumab

Brand name: Aduhelm

Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.

If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.

More Information on aducanumab (Aduhelm)

• Article Published in Health Matrix: The Journal of Law-Medicine: Public Citizen’s Advocacy Campaign Opposing FDA Approval of Aducanumab for Alzheimer’s Disease: The Fight Against Regulatory Capture, April 28, 2022
• Press Statement: CMS Resists Big Pharma Pressure Campaign, Makes the Right Call in Restricting Medicare Coverage for the Alzheimer’s Disease Drug Aducanumab, April 7, 2022
• Comments Submitted to CMS Regarding the Proposed National Coverage Determination for Aducanumab for Treatment of Alzheimer’s Disease, February 10, 2022
• Press Statement: CMS Follows the Science, Makes the Right Call in Proposing Medicare Coverage for the Alzheimer’s Disease Drug Aducanumab Only for Beneficiaries Who Enroll in a Randomized Clinical Trial, January 11, 2022
• Press Statement: FDA’s Reckless Decision to Approve Ineffective Alzheimer’s Disease Drug Causing Financial Pain for All Medicare Part B Beneficiaries, November 15, 2021
• Comments Submitted to the CMS Regarding the National Coverage Determination Analysis for Aducanumab Treatment of Alzheimer’s Disease, August 11, 2021
• Press Statement: Inspector General’s Decision To Investigate FDA’s Inappropriately Close Collaboration With Biogen on the Alzheimer’s Disease Drug Aducanumab Is Long Overdue, August 4, 2021
• Comments Prepared for the CMS Listening Session Regarding the National Coverage Determination Analysis for Aducanumab for Treatment of Alzheimer’s Disease, July 27, 2021
• Follow-up Letter to the HHS OIG Calling for Probe of Acting FDA Commissioner Woodcock’s Role in FDA’s Inappropriately Close Collaboration With Biogen, July 13, 2021
• Press Statement: Woodcock’s Role in Aducanumab’s Approval Must Be Investigated As Part of IG Probe, July 9, 2021
• Follow-up Letter to the HHS Office of Inspector General Requesting an Investigation of the FDA’s Unprecedented and Inappropriately Close Collaboration with Biogen on the Alzheimer’s Disease Drug Aducanumab, June 30, 2021
• Follow-up Letter to the HHS Secretary Calling for the Resignations of Acting FDA Commissioner, Other Top Officials Responsible for Indefensible Approval of the Alzheimer’s Disease Drug Aducanumab, June 30, 2021
• Letter to the HHS Secretary Calling for the Resignations of Acting FDA Commissioner, Other Top Officials Responsible for Indefensible Approval of the Alzheimer’s Disease Drug Aducanumab, June 16, 2021
• Press Statement: FDA’s Decision to Approve Aducanumab for Alzheimer’s Disease Shows Reckless Disregard for Science, Severely Damages Agency’s Credibility, June 7, 2021
• Letter to the Secretary of Health and Human Services Requesting an Investigation of the FDA’s Inappropriate Close Collaboration with Biogen on the Alzheimer’s Disease Drug Aducanumab, April 1, 2021
• Letter to the Editor of JAMA Neurology Regarding Lack of Clarity Regarding the Disclosure of Financial Conflicts of Interest, February 23, 2021
• Press Statement: FDA Must Demand a New Clinical Trial of Experimental Alzheimer’s Disease Treatment Following Inappropriate Collaboration, January 29, 2021
• Follow-up Letter to the FDA’s Acting Commissioner Regarding the Agency’s Inappropriate Close Collaboration with Biogen on the Alzheimer’s Disease Drug Aducanumab, January 28, 2021
• Letter to the FDA’s Regarding the Agency’s Inappropriate Close Collaboration with Biogen on the Alzheimer’s Disease Drug Aducanumab, December 9, 2020
• Letter to the HHS Office of Inspector General Requesting an Investigation of the FDA’s Inappropriate Close Collaboration with Biogen on the Alzheimer’s Disease Drug Aducanumab, December 9, 2020
• Testimony Before the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee Regarding Aducanumab for Treatment of Alzheimer’s Disease , November 6, 2020
• Press Statement: FDA Approval of Aducanumab to Treat Alzheimer’s Disease Would Be a Reckless Disregard for Science, Damage Agency’s Credibility, November 5, 2020